Armistice Capital, LLC and Steven Boyd filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 3,624,000 shares of Orthofix Medical Inc. common stock, representing 8.90% of the class as of September 30, 2026.

Key Highlights

  • Reporting persons: Armistice Capital, LLC (Delaware-organized investment adviser) and Steven Boyd (U.S. citizen), filing jointly as the "Reporting Persons."
  • Beneficial ownership: Each reporting person is attributed 3,624,000 shares of Orthofix Medical Inc. common stock, $0.10 par value per share.
  • Percent of class: The 3,624,000 shares represent 8.90% of the outstanding class, according to the filing.
  • Voting and dispositive power: Both reporting persons report 0 shares with sole voting or dispositive power, and 3,624,000 shares with shared voting and shared dispositive power.
  • Direct holder: The filing states the shares are directly held by Armistice Capital Master Fund Ltd., with Armistice Capital serving as its investment manager under an Investment Management Agreement.
  • Triggering date: The event requiring the filing occurred on September 30, 2026.

Armistice Capital and Boyd Disclose Joint 8.90% Position in Orthofix Medical

According to the Schedule 13G filed on November 16, 2026, Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 3,624,000 shares of Orthofix Medical Inc. (NASDAQ:OFIX) common stock. The filing identifies the triggering event date as September 30, 2026. Orthofix Medical Inc. is headquartered at 3451 Plano Parkway, Lewisville, TX 75056, as stated in the filing.

The filing explains that Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., described as the direct holder of the shares. "Pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund." Steven Boyd, identified as the managing member of Armistice Capital, is similarly attributed beneficial ownership of the same shares on that basis. The filing further notes that "the Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital."

Neither Armistice Capital nor Steven Boyd reports any sole voting or sole dispositive power over the 3,624,000 shares. All voting and dispositive power is reported as shared. The filing certifies that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

Armistice Capital, LLC and Steven Boyd filed a Schedule 13G disclosing a combined beneficial ownership of 3,624,000 shares, or 8.90%, of Orthofix Medical Inc. common stock as of September 30, 2026, with all voting and dispositive power held on a shared basis.